Group items tagged

A duodenoscope is a hollow, flexible, lighted tube that allows doctors to see the top of a patient's small intestine, or duodenum. It is used in diagnosis and treatment of severe, often life-threatening, diseases such as cancer or gallstones in the pancreas and bile ducts. The adoption of duodenoscopes is expected to increase significantly, owing to high prevalence of cancer and other chronic diseases. For instance, Japan recorded an age-standardized rate of 248 per 100,000 for cancer, as per Global Cancer Statistics 2018: GLOBOCAN. There are various different ways in which duodenoscopes can be used to help doctors see beyond the visible nose and throat area when performing a medical procedure. Nasal intraction with a duodenoscope is easiest performed with the device held horizontal and directly above the patient's nose and throat with the patient's chin slightly raised. When this procedure is performed correctly, there should be no visible scar from the edge of the windpipe to the base of the nose. Read more @ https://coherentmarketinsights-cmi.blogspot.com/2020/12/high-prevalence-of-cancer-and-other.html

Medical billing audits are a way to look for potential errors in a billing and coding process for a streamlined workflow & high reimbursement rate. Learn why such audits are important for any medical practice.

Medical billing audits are a way to look for potential errors in a billing and coding process for a streamlined workflow & high reimbursement rate. Learn why such audits are important for any medical practice.

Myelofibrosis Treatment includes medications and surgery. There are drugs and medicines which are used to cure myelofibrosis. Myelofibrosis is a muscle disease and various types of myelofibrosis treatment are available in the market to cure this condition. The muscle disease is caused due to myelodysplasia, a genetically determined trait that prevents the muscle from growing properly. Myelofibrosis is also known as spider veins, lying in regions close to the skin, like the armpits, groin, elbows, and knees. Myelofibrosis is the most common type of connective tissue disease. These medicines are generally used to control and stop the progress of the disease, after which, they suppress the activity of the immune system. Various types of steroids are used as medicines for myelofibrosis, to control the activity of the immune system and thereby stop the disease in its tracks. One of the most common drugs for myelofibrosis treatment is prednisone, which is generally used along with steroids. However, to treat spider veins and not myelofibrosis, a compound called Finasteride is used. The most important part of myelofibrosis treatment is a regular check-up, as early as 18 months of the disease a doctor can monitor the progress of the disease. Myelofibrosis treatment also includes physical therapy and other treatments to improve the symptoms of myelofibrosis. The main driving factor influencing the growth of the myelofibrosis treatment market is the increasing prevalence of myelofibrosis in emerging economies. For instance, according to Gleneagles Global Hospitals, the yearly incidence rate of myelofibrosis in India is 0.3 to 1.5 cases per 100,000 individuals. Most of the times these cases goes unnoticed since it is sometimes asymptomatic or less severe. Moreover, the market is estimated to grow owing to a large number of R&D investments, a large cluster of patients suffering from myelofibrosis, and better reimbursement policies. Read more @ https://coherentmarketinsights-bl

Pulmonary Arterial Hypertension (PAH) is a disease that affects the vasculature of the heart, specifically the arteries that transport blood from the heart to the lungs. Common symptoms include heart palpitations or an irregular rhythm, chest pain, coughing, wheezing, shortness of breath, chest discomfort when breathing, and sometimes even heart failure. The cause of pulmonary hypertension is not known, but research has indicated that genetic and hormonal factors may play a role in its development. The growing prevalence of Pulmonary Arterial Hypertension (PAH) is driving the growth of the Pulmonary Arterial Hypertension (PAH) Market. According to the European Respiratory Society, PAH is a rare disease, with an estimated prevalence ranging from 10 to 52 cases per million. The growing geriatric population is again increasing the prevalence of such disease which is also projected to foster the growth of the Pulmonary Arterial Hypertension (PAH) market. According to the United nation, by 2050, one in six people in the world will be over age 65 (16%), up from one in 11 in 2019 (9%). By 2050, one in four persons living in Europe and Northern America could be aged 65 or over. North America is projected to gain significant growth over the forecast period and this is attributed to the growing adoption of advanced treatment for treating pulmonary arterial hypertension. Moreover, increasing spending by the government on the healthcare sector is again augmenting the regional market growth. According to the U.S. Centers for Medicare & Medicaid Services, National health spending is projected to grow at an average annual rate of 5.4 percent for 2019-28 and to reach $6.2 trillion by 2028. Reads more @ https://coherentmarketinsights-blog.blogspot.com/2021/02/increasing-global-healthcare-spending.html

The environmental Health changes around are known and felt by all. Globally it is getting hotter; glaciers are melting at a faster rate, there are lesser trees around us, the sea level is rising, and so much more is happening around us.

All about lung cancer, causes risk factors, by Fostr multispeciality clinic. Lung cancer often has more particular symptoms until its advanced and has low rate of survival.

A contrast agent (also called a contrast medium) is an electrically charged material used in medical imaging to enhance the contrast of medical vessels or other tissues in the body. Contrast media/contrast agent either absorbs or changes ultrasound or electromagnetism, which is fundamentally different from radiopharms, which themselves emit electromagnetic radiation. This difference enables contrast agents to be applied to various body tissues with much higher strengths than their non-comp contrast counterparts. The most common contrast media/contrast agent used in medical imaging are CT contrast agents and MRI contrast agents. However, due to their non-magnetic nature, these medical imaging products are not able to be used on organ tissues, such as kidneys, hearts and lungs. Some manufacturers have now started manufacturing non-magnetic, biologically engineered CT and MRI contrast agents called mri-notherapy (mammography, radiofrequency ablation, and ultrasound contrast agents). High prevalence of cancer is expected to boost demand for contrast media. In the U.S., non-magnetic, biologically engineered CT and MRI contrast agents are now being used more frequently to treat patients with benign tumors of all types. Mri-notherapy is used for benign cancers of the breast (breast cancer), abdomen (belly fat), neck, head, joint (arthritis) and spine. Patients with melanoma, anemia, inoperable basilar artery disease, and multiple myeloma are also often treated with mri-notherapy. The therapy has a high success rate for benign tumors and very low incidence of mortality, espeacially in patients undergoing surgery. Moreover, recently, in November 2020, the U.S. FDA approved GE Healthcare's macrocyclic gadolinium-based MRI contrast agent, Clariscan (gadoterate meglumine), in pre-filled syringes. Read more @ https://coherentmarketinsights-cmi.blogspot.com/2020/12/high-prevalence-of-cancer-to-boost.html

Hyperphosphatemia is a condition caused by high levels of phosphorous or phosphate in the blood. This condition may be due to decreased emission of phosphate, excessive intake of phosphate, and the shift of phosphate from intracellular to extracellular. High phosphate levels in the blood can be avoided with the use of phosphate binders or by dietary restrictions. Phosphate is a chemical found in the human body and contains a mineral called phosphorous. It is important for the development of bones and teeth and also converts food into energy for the body. Some other possible causes of hyperphosphatemia include low levels of parathyroid hormone, high levels of vitamin D, uncontrolled diabetes, and diabetic ketoacidosis. The factors such as the growing geriatric population and increasing prevalence of chronic diseases worldwide are expected to drive the hyperphosphatemia drugs market in the coming future. Hyperphosphatemia is a primary cause of mortality and morbidity in people with chronic kidney disease. According to the Centers for Disease Control and Prevention (CDC), around 37 million adults in the United States are likely to have chronic kidney disease and most are undiagnosed. It is rare in the general population, but in people with chronic kidney disease, the rate of hyperphosphatemia is at least 70%. Since the increased risk of death from heart disease and hyperphosphatemia are associated with each other. This, in turn, increases the risk of heart disease in people suffering from hyperphosphatemia. Read more @ https://coherentmarketinsights-blog.blogspot.com/2020/12/increasing-prevalence-of-chronic-kidney.html

TRI Physical Therapy (PT) offers a hands-on, one-on-one approach to physical rehabilitation, improve movement and manage pain. Our top rated physical therapists provide a fundamentally new form of innovative and personalized rehabilitation care.

Looking for reliable and accurate medical coding audit services in the US? Our experienced team ensures coding compliance and accuracy, reducing errors and improving reimbursement rates. Enhance your revenue cycle management with our comprehensive services. Contact us today for a free consultation!

Penile Yeast infections in men are generally not known due to their lack of awareness. This severe illness can cause a range of infections that will affect hygiene and the fertility rate. And due to increasing cases of infertility in men, it becomes significant to acknowledge cautious infections in men to combat the rising infertility cases.

Being one of the infertility specialists in Noida, Dr. Sweta is a medical director of Crysta IVF, having rich experience of more than 25 years. She believes in providing the best infertility treatments to all patients with her expertise in handling more than 12000 IVF cycles in her entire medical journey. Additionally, she believes in ensuring a higher success rate with the latest medical advances for her patients with enough empathy and compassion Thus to regain the ability to become the parent of a child, It is significant to Visit Crysta IVF to get your treatment done by a prominent IVF specialist in Noida.

The healthcare revenue cycle is complex, and denial management is a critical aspect of it. Healthcare organizations need to understand the importance of effective denial management solutions to avoid revenue loss.

Looking for best IVF center in Mumbai? Visit pearl fertility and IVF clinic in Mumbai, our fertility experts will provide you best fertility and IVF services. Affordably priced IVF treatment. Doctors with IVF experience. High rate of IVF success.

Blocked blood vessels can complicate medical conditions that may result in fatality. As a result, artificial blood vessels are used to replace these damaged blood vessels. Artificial blood vessels refer to tubes made from various synthetic materials in order to restore and normalize blood circulation during disease conditions. They are mainly used to substitute aorta and are connected to two ends of blood vessels. These artificial blood vessels comprises biosynthetic materials like Polydioxanone and polyethylene terephthalate, due to mechanical properties such as high resistance against water and chemical, high oxygen permeability and high conductivity.

Discover how insurance participation can transform your medical practice and enhance patient care. Our latest article explores the vital role insurance networks play in maximizing opportunities for doctors. From expanding patient reach to optimizing reimbursement rates, learn how to thrive in today's healthcare landscape.

GBI Research found that the Travel Vaccines market in the top seven markets was valued at $1,343m in 2012, increasing at a Compound Annual Growth Rate (CAGR) of 11% during the 2007-2012 historic period. The market is projected to witness growth of 7.5% during the 2012-2019 forecast period to reach $2,224m.